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Paravalvular leaks occur in 5–17% of patients who underwent aortic or mitral valve
implantation. The patients who have a paravalvular leak mostly present with heart failure,
hemolytic anaemie, or both.The gold standard for treatment of severe symptomatic
paravalvular leaks is reoperation, which is, nevertheless, associated with increased
morbidity and is not always successful. Because of frequent patient morbidity and
increased risk of reoperation, there is a trend to favor the less invasive approach of initial
percutaneous closure without another sternotomy. The percutaneous approach requires
implantation of specially dedicated occlusive devices and a choice of three different access
sites: antegrade approach through femoral vein with transseptal puncture, retrograde
approach through femoral artery and transapical approach. PVL closure is a complex and
technically demanding intervention with a success rate between 40% and 90% and an
acceptable rate of adverse event. In a group of patients with a high risk of redo surgery the
percutaneous closure of PVL can lead to improving symptoms and outcomes.
& 2012 The Czech Society of Cardiology. Published by Elsevier Urban & Partner Sp.z o.o. All
rights reserved.
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Paravular leaks [PVL] are the most common significant
complication after the surgical valve replacement despite
their well-established and safe methodology. PVL are mostly
related to tissue friability, calcification, infection, but also
surgical techniques. The overall incidence of PVL is 5–17%,
there are more frequent in mechanical valves compared to
bioprosthetic valves. PVL is also more common in mitral
valves then aortic valves. The high overall incidence is based
on the transesophageal echocardiography [TEE] data and also
includes small, non-significant jets. The presence of clinically
relevant PVLs that need to be repaired is 1–5% among the
patients with artificial valves [1–5].2. Symptoms and clinical findings
The patients with significant PVL mostly suffer from symp-
toms of heart failure or hemolytic anaemia [or both]. When
the patient develops a worsening of shortness of breath, legs
swelling or he/she requires multiple transfusions, there is
common recommendation for the closure of the leak.3. Laboratory tests and echocardiography
Patients without hemolysis do not have any specific abnorm-
alities in laboratory tests. In contrast, patients with hemo-
lysis, especially with asymptomatic hemolysis, have reduced
hemoglobin levels, elevated lactate dehydrogenase activity
(LDH), changed reticulocyte counts and bilirubin levels, as
well as reduced haptoglobin concentrations.
The diagnosis is based on echocardiography findings. The
transthoracic [TTE] echo is often difficult to assess because
the pictures are obscured by calcium and sewing ring of the
artificial valves. The overshadowing of the PVL by mechan-
ical valves can lead to completely overlooking or under-
estimating the PVL. The gold standard is a transesophageal
echocardiography [TEE], which offers us a higher resolution
and sensitivity for the diagnosis. When we insert the TEE
probe to the oesophagus, behind the left atrium, the
position of the probe allows us to a get better picture and
the paravalvular jet is no longer obscured by the prosthetic
valve. The severity of the leak is defined by the same
criteria as are used for the quantification of valvular
regurgitation [6]. There are also well-known and accepted
indirect criteria which suggest the significance of aortic
PVL, such as reverse diastolic flow in descending aorta,
short pressure half time [PHT], increasing peak of trans-
valvular gradient, lack of left ventricular end-diastolic
diameter [LVEDD] reduction after surgical aortic valve
replacement [SAVR]. Similar indirect criteria of significant
mitral PVL are as follows: mean gradient 45 mmHg, the
prosthetic velocity time integral [VTI] to left ventricular
outflow tract [LVOT] VTI ratio 42.5, tricuspid regurgitation
velocity 43 m/s. Major progress in TEE in terms of PVL
imaging has been 3-dimensional reconstruction The three-
dimensional [3D] real time TEE can better recognize PVLsmorfology [numbers, sizes, shape] and the relation to the
other heart structures. 3D TEE can also help during the
transcatheter PVLs closure as a guidance and monitoring of
the procedure.4. Treatment
4.1. Open heart surgery
Surgical repair has been the standard treatment of the PVLs,
but it is usually associated with significant morbidity and
mortality. Moreover, surgery may not be successful since the
original anatomical problems persist. Because of these issues,
there is a strong interest in minimally invasive percutaneous
techniques that may allow successful treatment of paravalv-
ular regurgitation without another sternotomy [7–12].
Because of frequent patient morbidity and increased risk of
reoperation, there is a trend to favor the less invasive
approach of initial percutaneous closure. Surgical repair is
reserved for patients in whom percutaneous repair cannot be
performed or is contraindicated (e.g., active endocarditis,
significant dehiscence involving more than one-fourth of
the valve ring). Surgical treatment is also the first choice
when PVL is connected with dysfunction or instability of the
prosthetic valve, need for by-pass surgery [CABG] and infec-
tious endocarditis.
4.2. Catheter based treatment
The percutaneous approach requires implantation of spe-
cially dedicated occlusive devices and choice of the acces site.
There are three options: first femoral vein and transseptal
puncture mostly for treatment of mitral PVL, second femoral
artery for retrograde approach for closure of aortic and also
mitral PVLs. Finally, there is the transapical approch which
requires minor thoracotomy or direct puncturing of left
ventricle for treatment of mitral PVL. Despite the different
access site the main principles of the percutaneous closure of
PVL have been the same. At the beginning of the procedure it
is essential to move closer to PVL canal with well fitting
catheter, then pass through the canal with the guidewire and
place the guidewire to the appropriate heart chamber. The
next step is crucial—the guiding catheter should pass the
canal and then the dedicated occluder is deployed. The
selection of the occluder device is based on the shape of
PVL canal. In crescent-shaped PVL elipsoid AVP III could be
the appropriate option [Figs.1 and 2]. On the other hand,
round-shaped PVL can be closed by persistent ductus arter-
iosus [PDA] or ventricular septal defect [VSD]-dedicated
occluders. A very important issue is to choose the proper
size of the device. This is determined by the PVL canal
diameters as well as by the distance to the arteficial valve.
Especially in case of mechanical prosthetic valves there is a
risk of interference between the occluder device and the
disks of the prosthesis [Fig. 3]. There are several technical
issues which could made the procedure demanding. The first
issue is the localization and morfology of PVL track which
made serious difficulties to engage and cross it by the guide-
wire. The next problem is to pass the guidewire through the
Mechanical aortic prosthesis
Mechanical mitral
prosthesis
Tricuspid anuloplasty ring 
AVP III 
Fig. 2 – The Vascular plug III after releasing from delivery cable with a close relation to the aortic valve disk without any
consequences to the function of the prosthesis. Successful PVL closure.
AVP III
Delivery cable
Aortic mechanical valve
Mitral mechanical valve
Fig. 1 – The Vascular plug III with delivery cable in process of closure aortic PVL.
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the sewing ring. It is helpful to use telescopic coaxial system
coexisting with Judkins right 4 or Amplatz left 2 7French
guiding catheter and multipurpose 5French 125 cm long
catheter and exchange-length, extrasupport, angled, hydro-
philic 0.035-inch wire. In most cases, these systems allow
catheters to cross PVL canal without excessive force.
The transapical approach can be an alternative in mitral
PVL cases. It could be done as a first method of choice or as asecond procedure in terms of a failed attempt using the
percutaneous transfemoral route. Transapical procedure
should be performed in the hybrid operation room. The
procedure is performed under general anesthesia by lateral
minithoracotomy or direct percutaneous puncture of the
apex. The rationale for using the transapical approach is
based on the absence of needs for transseptal puncture and
challenging navigation in the left atrium. Morever, there is a
pure advantage of direct access to the valve. The experience
Mechanical aortic prosthesis
AVP III
interference
Fig. 3 – The Vascular plug III is in contact with disk of mechanical aortic prosthesis. This position of the Vascular plug is
incorrect and needs to be changed.
Table 1 – Published series of patients on transcatheter paravalvular leak closure.
Author No of leaks Year Valve Device Procedural success (%) Residual leak (%)
Hein [15] 21 2006 13 mitral, 8 aortic ASD,VSD, PDA 95 10
Sorraja [16] 19 2007 N.A. ASD, PDA 81 5
Pate [17] 10 2006 9 mitral, 1 aortic ASD, PDA, coil 50 40
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volume structural heart disease centers, however in most
cases the procedural success rate is high [13].5. Complications
Complications of PVL closure procedure are the following:
cardiac tamponade, access site bleeding, thrombembolic
complication, embolisation of the device and the malfunction
of the prosthetic valve due to interference with the occluder
device [14].
There are not very much data regarding the efficiency of
transcatheter PVL closure procedure. The long-term results of
percutaneous closure of prosthetic PVLs remain unknown.
Mostly the published data are based on the small numbers of
patients and short-term results. In most publications the
procedural success rate was between 50% and 90% [Table 1].
5.1. The Cardiocenter Podlesi Hospital data
Our group has had experience of 8 closure attempts (2 mitral
and 6 aortic leaks) performed on 7 patients. All aortic leaks
were approached retrogradely from the aorta, the both mitral
leaks were approached antegradely through a transseptalpuncture. 6 leaks have been successfully closed. Both proce-
dural failures, one aortic and one mitral, were due to inter-
ference of the device with the open disc of the valve. One of
these patients underwent a repeated procedure with a dif-
ferent type of device with the final procedural success. The
complications occurred in one patient with embolisation of
the device to the descending aorta. The device was success-
fully retrieved by the lasso catheter.6. Summary
There is no doubt that transcatheter PVL closure is a complex
and technically demanding intervention. The challenging
anatomy of the PVLs canal rules out successful crossing in
some patients, and device interference with the valve prohi-
bits device deployment in others. Because of the lack of
specific devices for closing these complex defects, there is a
lower rate of procedural success compared to other percuta-
neous interventions. On the other hand, the periprocedural
rate of adverse events appears to be acceptable for such high-
risk symptom limited patients. In group of patients with a
high risk of redo surgery the percutaneous closure of PVL can
lead to improving symptoms and outcomes. It should be
calculated with the needs for repeated procedures due to
c o r e t v a s a 5 4 ( 2 0 1 2 ) e 1 5 1 – e 1 5 5 e155residual leak, new leak development, and late dislodgement
of the device with leak recurrence. Transcatheter closure of
PVL seems to be a promising alternative for these patients,
but, honestly, we still have a long way to go before we
improve the outcomes.
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